Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amnis Introduces AutoSampler Option For ImageStreamX
The Amnis new option AutoSampler is expected to enhance productivity by enabling unattended sample loading from a wide variety of 96 well plates. The AutoSampler includes standard-height and
The Amnis new option AutoSampler is expected to enhance productivity by enabling unattended sample loading from a wide variety of 96 well plates. The AutoSampler includes standard-height and
According to Mylan Pharmaceuticals, the product was determined to be bioequivalent and, therefore, therapeutically equivalent to Pliva’s Hydroxyzine Hydrochloride tablets, a treatment for nervousness and tension.Hydroxyzine hydrochloride sold
Jevtana, a microtubule inhibitor, in combination with prednisone, was approved based on results from the Phase 3 Tropic clinical study involving 755 patients with mHRPC previously treated with
The court’s ruling narrowly defined several key phrases contained in Roquette’s patent claims, thereby dealing a significant blow to Roquette’s allegations of patent infringement. Reportedly, the court issued
The data indicated that Arikace, delivered once daily for 28 consecutive days followed by 56 days off-treatment for four cycles, demonstrated improvement in lung function that was sustained
Taspoglutide, a once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen’s research is developed by Roche, which is similar to the natural hormone
Entecavir is an oral antiviral drug used in the treatment of Hepatitis-B infection. It works by inhibiting reverse transcription, DNA replication and transcription in the viral replication process.
Cyntellec has said that Mr Zarrabian has been consulting with the company and has been acting CEO since March of 2010. Previously, he served as president and COO
Preliminary results of Canakinumab were presented at the annual European League Against Rheumatism (EULAR) meeting in Rome, Italy. In the six month Phase II study, Canakinumab has reduced
As per the terms of collaboration agreement that signed on March 30, 2007, CanBas and Takeda’s wholly-owned subsidiary Millennium: The Takeda Oncology had jointly initiated Phase II trials